

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies ID3845

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Astellas Pharma Ltd (enfortumab vedotin) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action Bladder Cancer UK • Black Health Agency • Bladder and Bowel UK • Cancer 52 • Cancer Black Care • Cancer Equality • Fight Bladder Cancer • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Pelican Cancer Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Gynaecological Cancer Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society of Urogenital Radiology • British Society of Urogynaecology • British Uro-Oncology Group • Cancer Research UK 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (docetaxel, paclitaxel) • Celgene (paclitaxel) • Hospira UK (docetaxel, paclitaxel) • Seacross Pharmaceuticals (docetaxel, paclitaxel) • Teva UK (paclitaxel) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Urology • Genomics England • Heart Research UK • Institute of Cancer Research • MRC Clinical Trials Unit

Provisional stakeholder list for the proposed technology appraisal of enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies ID3845

Issue date: February 2021

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society • Urology Foundation <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Sheffield CCG • NHS Wokingham CCG • Welsh Government 	<ul style="list-style-type: none"> • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Urothelial Cancers Research Group, Leeds Institute of Cancer & Pathology <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.)

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.